scholarly journals Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population

2017 ◽  
Vol Volume 13 ◽  
pp. 515-526 ◽  
Author(s):  
Kaida Jiang ◽  
Lingjiang Li ◽  
Wang Xueyi ◽  
Maosheng Fang ◽  
Jianfei Shi ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Prospective Study ◽  
Chinese Population ◽  
Anxiety Symptoms ◽  
Open Label ◽  
Major Depressive

scholarly journals Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study

2021 ◽  
Vol 11 ◽  
pp. 204512532110131
Author(s):  
Pratap Chokka ◽  
Holly Ge ◽  
Joanna Bougie ◽  
Anders Ettrup ◽  
Guerline Clerzius
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Treatment Outcomes ◽  
Clinical Symptoms ◽  
Work Productivity ◽  
Anxiety Symptoms ◽  
Open Label ◽  
Major Depressive ◽  
Severe Anxiety

Background: Anxiety symptoms are common in patients with major depressive disorder (MDD) and usually confer worse treatment outcomes. The long-term, open-label AtWoRC study in working patients with MDD treated with vortioxetine demonstrated a significant correlation between severity of anxiety symptoms and impaired work productivity. This analysis was undertaken to further explore clinical characteristics and treatment outcomes in patients with different levels of severity of anxiety symptoms at baseline. Methods: Post hoc analysis in 199 working patients with MDD treated with vortioxetine (10–20 mg/day), stratified by Generalized Anxiety Disorder 7-item (GAD-7) score at baseline [mild/moderate anxiety (GAD-7 ⩽14), n = 83; severe anxiety (GAD-7 ⩾15), n = 116]. Associations were examined between GAD-7 and other outcome assessment scores at baseline. Observed mean changes from baseline to week 52 were compared between groups. Results: Patients with severe anxiety had significantly worse depressive and cognitive symptoms, functioning, and work productivity at baseline than those with mild/moderate anxiety, but similar cognitive performance. Statistically significant improvements from baseline were seen for all outcomes after 52 weeks of vortioxetine treatment, with no significant differences observed between the two groups after adjustment for baseline anxiety scores. Conclusion: Treatment with vortioxetine was associated with long-term improvement in clinical symptoms and measures of work productivity in patients with MDD in a real-world setting, irrespective of severity of anxiety symptoms at the start of treatment.

scholarly journals A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms

2016 ◽  
Vol 206 ◽  
pp. 140-150 ◽  
Author(s):  
David S. Baldwin ◽  
Ioana Florea ◽  
Paula L. Jacobsen ◽  
Wei Zhong ◽  
George G. Nomikos
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Meta Analysis ◽  
Anxiety Symptoms ◽  
Major Depressive

Zuranolone in Major Depressive Disorder: Interim Safety Results From a Phase 3, Open-Label, Longitudinal Study

2021 ◽  
Vol 89 (9) ◽  
pp. S161
Author(s):  
Andrew Cutler ◽  
Scott T. Aaronson ◽  
Gregory W. Mattingly ◽  
Samuel T. Wilkinson ◽  
Robert Lasser ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Longitudinal Study ◽  
Depressive Disorder ◽  
Open Label ◽  
Major Depressive ◽  
Phase 3
Sign in / Sign up

Export Citation Format

Share Document